Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension
Science Translational Medicine · 20.05.2026 · 18 (850)
DOI: 10.1126/scitranslmed.ads5175 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 20.05.2026. Verfasst von Rowena J Jones und 24 weiteren Autor:innen. Beteiligte Einrichtung: Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, UK. Hauptthemen laut MEDLINE: Signal Transduction, Bone Morphogenetic Proteins, Pulmonary Arterial Hypertension, Recombinant Fusion Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: NIHR BioResource, Medical Research Council, British Heart Foundation.
Abstract (Originalsprache)
Pulmonary arterial hypertension (PAH) is a rare, life-limiting disease where imbalances in the transforming growth factor–β (TGF-β) and bone morphogenetic protein receptor type II (BMPR-II) superfamily pathways have causal roles in hereditary and idiopathic forms of the disease. These pathways are emerging attractive candidates for therapeutic intervention, but there is an unmet need for clinically relevant and practical biomarkers that can measure target engagement, partly because of the inaccessibility of lung tissue in disease for molecular profiling. Here, we explored the surrogate capacity of peripheral blood bone morphogenetic protein (BMP) pathway–specific markers using samples collected in the StratosPHere 1 study using both cell surface assessment of BMPR-II receptor levels and quantitative PCR for the assessment of downstream target engagement. Downstream BMPR-II canonical and noncanonical signaling was measurable and altered in whole blood in both discovery and international replication cohorts, and transcriptomic signatures were clustered by discrete gene modules that associated with clinical outcomes and mortality. We derived a transcriptomic biomarker panel that was repeatable, reproducible, and longitudinally stable for use in early phase, target engagement clinical trials. The biomarker panel was used in a pilot study of nine sotatercept-treated patients with PAH to test the effect of the therapy on the BMP pathway; analysis suggested that sotatercept did not rebalance or increase BMPR-II pathway signaling but rather led to a reduction, possibly due to depletion of circulating BMP9 and BMP10.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, UK.
- Royal Papworth Hospital, Cambridge, UK.
- MRC Biostatistics Unit, University of Cambridge, Biomedical Campus, Cambridge, UK.
- MEMOTEF, Sapienza University of Rome, Rome, Italy.
- Université Paris-Saclay, Hypertension Pulmonaire: Physiopathology and Innovation Thérapeutique, HPPIT, Faculté de Médecine, Le Kremlin-Bicêtre, France.
- INSERM UMR_S 999, HPPIT, Le Kremlin-Bicêtre, France.
ORCID-Profile: Rowena J Jones, Eckart M D D De Bie, Nina Deliu, Anthony Y K C Ng, Stefan Gräf, Christophe Guignabert, Marc Humbert, Laurent Savale, Ly Tu, Athénäis Boucly, Joseph Newman, Gary Polwarth, Paul D Upton, Allan Lawrie, Christopher J Rhodes, Martin R Wilkins, Sarah K Binmahfooz, Alexander M K Rothman, Anna Hemnes, Sofía S Villar, James West, Mark R Toshner
Förderung
- NIHR BioResource
- Medical Research Council
- British Heart Foundation
- Gates Cambridge Trust
- NIHR Imperial Biomedical Research Centre
- Department of Health
- NIHR Sheffield Biomedical Research Centre
- Cambridge Biomedical Research Centre
Zitieren
APA
Jones, R. J., De Bie, E. M. D. D., Deliu, N., Ng, A. Y. K. C., Dunmore, B. J., Gräf, S., Guignabert, C., Humbert, M., Savale, L., Tu, L., Boucly, A., Newman, J., Polwarth, G., Upton, P. D., Lawrie, A., Rhodes, C. J., Wilkins, M. R., Binmahfooz, S. K., Rothman, A. M. K., …, & Toshner, M. R. (2026). Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension. Science Translational Medicine, 18(850). https://doi.org/10.1126/scitranslmed.ads5175
Vancouver
Jones RJ, De Bie EMDD, Deliu N, Ng AYKC, Dunmore BJ, Gräf S, et al. Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension. Science Translational Medicine. 2026;18(850). doi:10.1126/scitranslmed.ads5175
BibTeX
@article{Jones2026,
author = {Jones, Rowena J and De Bie, Eckart M D D and Deliu, Nina and Ng, Anthony Y K C and Dunmore, Benjamin J and Gräf, Stefan and Guignabert, Christophe and Humbert, Marc and Savale, Laurent and Tu, Ly and Boucly, Athénäis and Newman, Joseph and Polwarth, Gary and Upton, Paul D and Lawrie, Allan and Rhodes, Christopher J and Wilkins, Martin R and Binmahfooz, Sarah K and Rothman, Alexander M K and Hemnes, Anna and Villar, Sofía S and West, James and UK National Cohort Study of Idiopathic and Heritable PAH Consortium, UK National Cohort Study of Idiopathic and Heritable PAH Consortium and Uniphy Clinical Trials Network, Uniphy Clinical Trials Network and Toshner, Mark R},
title = {Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension},
journal = {Science Translational Medicine},
year = {2026},
volume = {18},
number = {850},
doi = {10.1126/scitranslmed.ads5175}
}
EUVIMED